Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Other financing activities (2019 - 2025)

Pulmonx (LUNG) reported Other financing activities of $23000.0 for Q3 2025, down 56.6% on a QoQ basis from $53000.0 in Q4 2022.

Pulmonx (LUNG) has 5 years of Other financing activities data on file, last reported at $23000.0 in Q3 2025.

  • Quarterly Other financing activities changed N/A year-over-year to $23000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $76000.0 (up 43.4% YoY) and the FY2022 annual result came in at $53000.0, up 29.27% from the prior year.
  • Other financing activities retreated to $23000.0 in Q3 2025 per LUNG's latest filing, from $53000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $100000.0 in Q1 2021 and bottomed at -$59000.0 in Q2 2021.
  • The 3-year median for Other financing activities is $38000.0 (2022), against an average of $29250.0.
  • Peak annual rise in Other financing activities reached 21.95% in 2021, while the deepest fall reached 195.16% in 2021.
  • Tracing LUNG's Other financing activities over 3 years: stood at -$59000.0 in 2021, then surged by 189.83% to $53000.0 in 2022, then sank by 56.6% to $23000.0 in 2025.
  • Per Business Quant, the three latest LUNG Other financing activities figures stand at $23000.0 (Q3 2025), $53000.0 (Q4 2022), and -$59000.0 (Q2 2021).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Pulmonx 67.30 Mn -2.45 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2025 23,000.00
Sep 30, 2025 23,000.00
Dec 31, 2022 53,000.00
Dec 31, 2022 53,000.00
Jun 30, 2021 -59,000.00
Jun 30, 2021 -59,000.00
Mar 31, 2021 100,000.00
Mar 31, 2021 100,000.00
Dec 31, 2020 -2.57 Mn
Dec 31, 2020 -2.57 Mn
Sep 30, 2020 2.57 Mn
Sep 30, 2020 2.57 Mn
Jun 30, 2020 62,000.00
Jun 30, 2020 62,000.00
Mar 31, 2020 82,000.00
Mar 31, 2020 82,000.00
Dec 31, 2019 -21,000.00
Dec 31, 2019 -21,000.00